NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal (Committee A) meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 2 March 2021, 9:30am – 7:05pm

**Location:** via Zoom

## Committee members present:

1. Dr Jane Adam (Chair) Present for all items
2. Dr Brian Shine (Vice Chair) Present for all items
3. Mr Peter Baker Present for items 1 to 6.1.3.
4. Mr Richard Ballerand Present for all items
5. Dr Andrew Champion Present for all items
6. Dr Justin Daniels Present for items 1 to 4
7. Dr Steve Edwards Present for all items
8. Dr Rita Faria Present for all items
9. Dr Rishiraj Hazarika Present for all items
10. Professor Khalida Ismail Present for items 1 to 6.1.3.
11. Ms Sumithra Maheswaran Present for items 1 to 5.1.3.
12. Professor G.J. Melendez-Torres Present for all items
13. Ms Sarah Parry Present for all items
14. Mrs Becky Pennington Present for all items
15. Mr Dominic Pivonka Present for items 1 to 4
16. Dr Mohit Sharma Present for all items
17. Dr Stephen Sharp Present for items 1 to 5.2
18. Mr Min Ven Teo Present for all items
19. Dr Alice Turner Present for items 1 to 6.2
20. Dr Roger Whittaker Present for all items

## NICE staff present:

Janet Robertson, Associate Director Present for all items

Thomas Feist, Project Manager Present for items 1 to 5.1.3., 6 and 7

Ewa Rupniewska, Technical Advisor Present for items 1 to 4

Caroline Bregman, Technical Analyst Present for items 1 to 4

Rebecca Thomas, Assistant Technical Analyst Present for items 1 to 4

Mary Hughes, Technical Advisor Present for item 5

Sana Khan, Technical Analyst Present for item 5

Zoe Charles, Technical Analyst Present for items 5 to 7

Richard Mattock, Technical Lead (Contractor YHEC) Present for items 5 to 7

Lucasz Grodzicki, Technical Lead (Contractor YHEC) Present for items 5 to 7

Emily Eaton Turner, HTA Adviser Present for all items

Claire Hawksworth, Evidence Generation Present for items 1 to 4

Ria Skelton, Senior Medical Editor Present for items 6 and 7

Olivia Havercroft, Medical Editor Present for item 5

Sarah Bromley, Senior Medical Editor Present for item 1 to 4

Adam Storrow, Resource Impact Team Present for all items

Heidi Livingstone, Senior Public Involvement Adviser Present for items 5.1 and 6.1

Mandy Tonkinson, Public Involvement Advisor Present for items 1 to 4.1

Ian Wall, Assistant Project Manager Present for items 1 to 4.1

Lucinda Evans, Coordinator Present for items 1 to 4.1 and 6.1

Sandra Robinson, Coordinator Present for items 1 to 4.1 and 5.1

Mira Patel, Coordinator Present for all items

Gemma Smith, Coordinator Present for item 5

Sophie McHugh, Administrator Present for item 5

Marcia Miller, Administrator Present for all items

Daniel Greenwood, Assistant Administrator Present for items 6 and 7

## External group representatives present:

James Mahon, Health Economist, Liverpool Reviews Present for items 1 to 4.1 and

and Implementation Group 6.1

Marty Chaplin, Medical Statistician, Liverpool Reviews Present for items 1 to 4.1 and

and Implementation Group 6.1

Marta Soares, Senior Research Fellow, [University of York](http://niceplan2/Appraisals_TestLive/Stakeholders17.aspx?ACID=1419) Present for item 5.1

Mark Simmonds, Senior Research Fellow, [University of York](http://niceplan2/Appraisals_TestLive/Stakeholders17.aspx?ACID=1419) Present for item 5.1

## Professional experts present:

Professor Peter Schmid, clinical expert, Centre Lead, Present for items 1 to 4.1.3.

Centre of Experimental Cancer Medicines (Bart’s),

nominated by Daiichi Sankyo.

Holly Heath, patient expert, Policy Manager at Breast Present for items 1 to 4.1.3.

Cancer Now, nominated by Breast Cancer Now.

Claire Myerson, patient expert, nominated by Breast Present for items 1 to 4.1.3.

Cancer Now.

Professor Peter Clark, CDF Clinical Lead, NHSE&I. Present for items 1 to 4

Dr Raj Sengupta, clinical expert, Consultant Present for item 5.1

Rheumatologist at Royal National Hospital for

Rheumatic Diseases, Bath, nominated by Novartis.

Dr Louise Warburton, clinical expert, Associate Medical Present for items 5.1 and 6.1

Director, Primary Care Rheumatology and MSK

Medicine Society, nominated by PCRMMS.

Dr Helena Marzo-Ortega, clinical expert, Consultant Present for items 6.1

Rheumatologist and Honorary Clinical Associate Professor,

Leeds Teaching Hospital, nominated by Novartis.

Nick Clarke, patient expert, nominated by National Axial Present for items 6.1

Spondyloarthritis Society

## Observers present:

Harsimran Sarpal, Technical Analyst, NICE Present for items 1 to 4

Conrad Harrison, Scholar, NICE Present for all items

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Ms Pamela Rees.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on 10 November 2020 and 2 February 2021.

### Appraisal of Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]

* 1. Part 1 – Open session
     1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Daiichi Sankyo UK.
     2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor Peter Schmid, clinical expert, declared direct financial interests as he had received consultancy fees and honorarium from the following: AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Pfizer, Puma, Roche, Daiichi.

Prior to the meeting, Professor Schmid declared further direct financial interests, specific to Daiichi Sankyo, as he is the National Advisory Board Chair since 27 March 2020, attended the European Advisory Board meeting on 4 February 2020 and was a principal investigator Destiny trial programme. Professor Schmid also declared indirect interests as his institution had received funding from the following: Astellas, AstraZeneca, Genentech, Novartis, Oncogenex, Roche.

It was agreed that these declarations would not prevent Professor Schmid from providing expert advice to the committee.

* Holly Heath, patient expert, declared indirect interests as her employer, Breast Cancer Now, received funding from various pharma companies, including a grant to the helpline from Daiichi Sankyo in autumn 2020, for £22,559. It was agreed that this declaration would not prevent Holly from providing expert advice to the committee.
* Prior to the meeting, Claire Myerson, patient expert, declared direct financial interests as she had received honoraria in the past year for patient advocacy advice and input to breast cancer patient information projects at Novartis Pharma Corporation/Novartis UK. Claire also declared direct non-financial interests as in the past year, she was a volunteer member of CRUK Patient Insights Panel, giving patient advocacy advice/input to projects at CRUK. She also contributed her patient experience to Breast Cancer Now fundraising and awareness campaigns. It was agreed that these declarations would not prevent Claire from providing expert advice to the committee.

No further conflicts of interest were declared for this item.

* + 1. The Chair introduced the lead team, Dr Andrew Chapman and Dr Steve Edwards, who gave presentations on the clinical effectiveness and cost effectiveness of Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697].
  1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting)
     1. The committee discussed confidential information submitted for this item.
     2. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

* 1. Part 1 – Open session
     1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Novartis Pharmaceuticals.
     2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Mr Dominic Pivonka, Committee Member, declared direct financial interests as his employer, AbbVie, is a comparator company (adalimumab) for this treatment, and has another treatment recently licensed for ankylosing spondylitis, upadacitinib. It was agreed that this declaration would prevent Mr Pivonka from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
* Dr Rita Faria, committee member, declared indirect interests as she works at the same university as the Evidence Review Group for this appraisal. She had no knowledge or input into this appraisal prior to it being discussed at committee. It was agreed that this declaration would not prevent Dr Faria from participating in this section of the meeting.
* Dr Raj Sengupta, clinical expert, declared direct financial interests as he received grants, honoraria for advisory boards, speaker event fees and support for conference attendance from Novartis, Abbvie, Biogen, Celgene, Lilly, MSD, Roche and UCB. It was agreed that this declaration would not prevent Dr Sengupta from providing expert advice to the committee.
* Dr Louise Warburton, clinical expert, declared direct financial interests as she partook in a webinar talk for MIMS Live on Osteoporosis which was pharma sponsored in November 2020. Dr Warburton also declared direct non-financial interests as she is a NICE fellow and is on the Executive Committee of the Primary Care Rheumatology and MSK Medicine Society, supported by pharma. It was agreed that these declarations would not prevent Dr Warburton from providing expert advice to the committee.
* No further conflicts of interest were declared for this item.
  + 1. The Chair introduced the lead team, Professor Khalida Ismail, Dr Brian Shine and Mr Richard Ballerand, who gave presentations on the clinical effectiveness and cost effectiveness of Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419].
  1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
     2. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

* 1. Part 1 – Open session
     1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Eli Lilly and Company.
     2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Mr Dominic Pivonka, Committee Member, declared direct financial interests as his employer, AbbVie, is a comparator company (adalimumab) for this treatment, and has another treatment recently licensed for ankylosing spondylitis [ID3848] Upadacitinib. It was agreed that this declaration would prevent Mr Pivonka from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
* Dr Helena Marzo-Ortega, clinical expert, declared direct financial interests as she had received research grants from Janssen and Novartis, and had received speaker fees/consultancy fees/honoraria from Celgene, Janssen, Eli- Lilly, Novartis, Pfizer, Takeda and UCB. Dr Marzo-Ortega declared further direct financial interests as she partook in medical advisory boards with Eli Lilly in April 2019, Nov 2019 and Dec 2020, as well as being a speaker at EULAR Symposium in June 2020, which was supported by Eli Lilly. It was agreed that these declarations would not prevent Dr Marzo-Ortega from providing expert advice to the committee.
* Dr Louise Warburton, clinical expert, declared direct financial interests as she partook in a webinar talk for MIMS Live on Osteoporosis which was pharma sponsored in November 2020. Dr Warburton also declared direct non-financial interests as she is a NICE fellow and is on the Executive Committee of the Primary Care Rheumatology and MSK Medicine Society, supported by pharma. It was agreed that these declarations would not prevent Dr Warburton from providing expert advice to the committee.
* No further conflicts of interest were declared for this item.
  + 1. The Chair introduced the lead team, Dr Roger Whittaker, Professor G.J Melendez-Torres and Mr Richard Ballerand, who gave presentations on the clinical effectiveness and cost effectiveness of Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532].
  1. Part 2 - Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
     2. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal (Committee A) will be held on Wednesday 7 April 2021 and will start promptly at 9:30am.